Xiwang Pharmaceutical Co., Ltd. Dextrose

Xiwang Pharmaceutical Co., Ltd. announced that its core product, glucose raw material, has successfully passed the EU CEP (Certificate of Suitability) certification, marking its official access to the EU market and a significant leap forward in its international competitiveness. This is another important breakthrough for Xiwang Pharmaceutical in the high-end international market, following its certifications by the US FDA and Japan PMDA.

As a leading enterprise in the domestic starch sugar raw material industry, Xiwang Pharmaceutical has focused on the research and development and production of glucose series products for over 20 years. With an annual production capacity of 300,000 tons of glucose raw material, it is one of the world's largest glucose production bases. The company's glucose products cover multiple varieties, including anhydrous glucose, monohydrate glucose, and oral glucose, with a purity of 99.5%-99.9%, and are widely used in pharmaceuticals, food, and chemical industries. The glucose raw material that has now passed CEP certification adopts internationally advanced fully enclosed production technology, achieving full-chain quality control from corn raw materials to finished products. Key quality indicators all meet or exceed European Pharmacopoeia standards.

A quality manager at Xiwang Pharmaceutical stated, "The successful CEP certification is a high recognition of the quality of Xiwang Pharmaceutical's glucose products and its production management system. In the future, the company will continue to increase investment in research and development, optimize its product structure, and further expand into international markets, allowing Xiwang glucose products to benefit more customers worldwide." It is understood that Xiwang Pharmaceutical's glucose raw materials have been exported to more than 50 countries and regions worldwide, establishing a high-quality image for "Made in China" in the international market.

This successful certification not only enhances Xiwang Pharmaceutical Co., Ltd.'s position in the global pharmaceutical supply chain but also provides an important reference for the Chinese glucose raw material industry to participate in international competition, demonstrating the strong capabilities of Chinese pharmaceutical manufacturing.